NASDAQ:BOLD Audentes Therapeutics (BOLD) Stock Price, News & Analysis → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Free BOLD Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$11.17▼$11.9050-Day Range$59.97▼$59.9752-Week Range$22.00▼$60.00Volume151,319 shsAverage Volume1.50 million shsMarket Capitalization$522.87 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsInsider TradesSocial MediaStock AnalysisCompetitorsInsider TradesSocial Media Get Audentes Therapeutics alerts: Email Address Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! About Audentes Therapeutics Stock (NASDAQ:BOLD)Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.Read More Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! BOLD Stock News HeadlinesApril 11, 2024 | bbc.co.ukBold GirlsApril 11, 2024 | businesswire.comBoundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene AmplificationsApril 19, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.April 11, 2024 | morningstar.comBoundless Bio Inc BOLDApril 8, 2024 | businesswire.comBoundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024March 27, 2024 | businesswire.comBoundless Bio Announces Pricing of Initial Public OfferingNovember 25, 2023 | cnn.comMarriott Bonvoy Bold credit card review 2023November 4, 2023 | yahoo.comKristen Louelle Is Bold and Beautiful in These 4 Pics in Atlantic CityApril 19, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.October 27, 2023 | usatoday.comWhat Top 25 upsets are coming this weekend? Bold predictions for Week 5 in college footballApril 27, 2023 | forbes.comHow Bold Leadership Can Help Or Hurt YouApril 23, 2023 | finance.yahoo.comBold Therapeutics Presents Jaw-Dropping Interim Phase 2 Clinical Data for BOLD-100 in the Treatment of Advanced Colorectal Cancer at AACR 2023April 18, 2023 | entrepreneur.comThe Benefits of Bold Leadership and How Leaders Can Develop a Bold MindsetApril 2, 2023 | usatoday.comFive bold predictions for the men's NCAA Tournament's Final FourMarch 26, 2023 | usatoday.comMen's NCAA Tournament 2023: 10 bold predictions for March MadnessMarch 23, 2023 | finance.yahoo.com5AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough ScienceMarch 17, 2023 | forbes.comTikTok Has A New ‘Bold Glamour’ AI-Powered Filter, Here Are The RisksMarch 12, 2023 | yahoo.comYou but better? Not so fast. Unpacking TikTok's controversial 'Bold Glamour' filterJanuary 18, 2023 | news.yahoo.comOn King's holiday, daughter calls for bold action over wordsJanuary 17, 2023 | dailymail.co.ukIt's blue Monday... Let's embrace it says JO ELVIN, with this season's refreshingly bold take on the colourJanuary 13, 2023 | forbes.comPersonal And Career Success One Bold Move A DayJanuary 5, 2023 | theguardian.comLeBron exits LA and an American F1 star: our bold sports predictions for 2023November 14, 2022 | usatoday.comBold predictions for college football's Week 11 have Alabama and LSU on upset alertOctober 8, 2022 | nypost.comLEGO makes bold claim on how bricks affect mental healthAugust 24, 2022 | investing.comBOLD_old Historical DataAugust 22, 2022 | yahoo.comFDA approves first fast-acting oral drug for clinical depressionMarch 18, 2022 | yahoo.comAppnovation Earns Seven 2022 MUSE Creative AwardsSee More Headlines Receive BOLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Audentes Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2019Today4/19/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:BOLD CUSIPN/A CIK1628738 Webwww.audentestx.com Phone415-818-1001FaxN/AEmployees207Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-128,820,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-38.00% Debt Debt-to-Equity RatioN/A Current Ratio12.80 Quick Ratio12.79 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($7.48) per share Price / Book-1.51Miscellaneous Outstanding Shares46,272,000Free FloatN/AMarket Cap$522.87 million OptionableNo Data Beta2.18 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Matthew R. Patterson (Age 47)Co-Founder, Chairman & CEO Ms. Natalie C. Holles (Age 46)Pres & COO Mr. Thomas P. Soloway (Age 52)Exec. VP & CFO Dr. John T. Gray (Age 56)Sr. VP & Chief Scientific Officer Mr. Andrew H. ChangDirector of Investor RelationsKey CompetitorsTaysha Gene TherapiesNASDAQ:TSHAEditas MedicineNASDAQ:EDITAlectorNASDAQ:ALECC4 TherapeuticsNASDAQ:CCCCExscientiaNASDAQ:EXAIView All CompetitorsInsidersRa Capital Management, L.P.Bought 312,500 shares on 4/2/2024Total: $5 M ($16.00/share)Kristina BurowBought 200,000 shares on 4/2/2024Total: $3.20 M ($16.00/share)View All Insider Transactions BOLD Stock Analysis - Frequently Asked Questions How were Audentes Therapeutics' earnings last quarter? Audentes Therapeutics Inc (NASDAQ:BOLD) released its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.07. During the same period last year, the company posted ($0.97) EPS. What other stocks do shareholders of Audentes Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Audentes Therapeutics investors own include Energy Transfer (ET), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Intel (INTC), Clovis Oncology (CLVS), AbbVie (ABBV), bluebird bio (BLUE), Ford Motor (F), Global Blood Therapeutics (GBT) and Myriad Genetics (MYGN). When did Audentes Therapeutics IPO? Audentes Therapeutics (BOLD) raised $100 million in an initial public offering (IPO) on Thursday, March 28th 2024. The company issued 6,250,000 shares at $16.00 per share. When does Audentes Therapeutics' quiet period expire? Audentes Therapeutics' quiet period expires on Tuesday, May 7th. Audentes Therapeutics had issued 6,250,000 shares in its IPO on March 28th. The total size of the offering was $100,000,000 based on an initial share price of $16.00. During Audentes Therapeutics' quiet period, underwriters and any insiders that worked on the IPO are prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company. This page (NASDAQ:BOLD) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe “Perfect Storm” for GoldGold Safe ExchangeThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingBiden’s $374B Giveaway Into This SectorDTIYour Money is Not SafeAmerican AlternativeHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceSHOCKING Crypto Leak…Crypto 101 MediaMy biggest AI fearParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Audentes Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.